You are here

XRpro Radioactive Cesium Decorporation Agents

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI091186-01A1
Agency Tracking Number: R43AI091186
Amount: $600,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA12-044
Timeline
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-07-01
Award End Date (Contract End Date): 2017-06-30
Small Business Information
4222 Emperor Blvd, Suite 350
Durham, NC 27703
United States
DUNS: 147452275
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BENJAMIN WARNER
 (505) 412-2345
 warner@palladias.com
Business Contact
 BENJAMIN WARNER
Phone: (505) 412-2345
Email: sdeering@icagen.com
Research Institution
N/A
Abstract

DESCRIPTION provided by applicant Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation nuclear emergencies high priority for DHHS NIH NIAID DAIT and a critical need for the Strategic National Stockpile SNS Calderaandapos s agent will select for Cs over potassium K sodium Na and other elements that are essential for human health Current treatments are non selective and must be used under strict clinical supervision Selectivity is needed because Na and K are more prevalent than Cs in the body non selective decorp agents are swamped by Na and K Na K and Cs have similar properties so selective treatments are traditionally very difficult to develop Agents such as Prussian Blue PB are current treatments for Cs exposure however PB only binds Cs from the gastrointestinal tract GI DTPA analogs have been approved by the FDA for treatment of plutonium americium and curium but they are in intravenous forms so are difficult to administer in response to mass exposure Calderaandapos s approach focuses on chelating radioactive Cs in blood and muscle that has been absorbed systemically from all exposure routes oral dermal inhaled There are no decorp agents to selectively remove Cs from the bloodstream and musculature Caldera will use XRpro r a high throughput screening HTS label free x ray fluorescence XRF technology to produce selective decorp agents for Cs and other radioisotopes XRpro r protocols instruments microarrays and novel ligands increase the signal and decrease the noise for measuring Cs increasing the likelihood that Phase I will result in novel selective Cs decorp agents PUBLIC HEALTH RELEVANCE Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation nuclear emergencies high priority for DHHS NIH NIAID DAIT and a critical need for the Strategic National Stockpile SNS Calderaandapos s agent will select for Cs over potassium K sod ium Na and other elements that are essential for human health Current treatments are non selective and must be used under strict clinical supervision

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government